secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantheus Holdings, Inc. (LNTH)
CIK:        0001521036
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001193125-25-004904
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Lantheus to Acquire Life Molecular Imaging for $350M Upfront with Potential $400M Earnout
--------------------------------------------------------------------------------

- Upfront cash payment of $350M for Life Molecular Imaging, with up to $400M in potential earnout and milestone payments.
- Acquisition adds Neuraceq (florbetaben F18), an FDA-approved PET imaging agent for Alzheimer's disease diagnosis.
- Lantheus will assume up to $30M in seller's retained contingent liabilities under certain contractual arrangements.
- Transaction expected to close in H2 2025, subject to Life Healthcare shareholder vote, antitrust clearances, and SA Reserve Bank approval.
- Lantheus expects the deal to be accretive to adjusted EPS within 12 months of closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1521036/000119312525004904/0001193125-25-004904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1521036/000119312525004904/d860596d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-004904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer